ATE459352T1 - Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe - Google Patents
Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppeInfo
- Publication number
- ATE459352T1 ATE459352T1 AT07786974T AT07786974T ATE459352T1 AT E459352 T1 ATE459352 T1 AT E459352T1 AT 07786974 T AT07786974 T AT 07786974T AT 07786974 T AT07786974 T AT 07786974T AT E459352 T1 ATE459352 T1 AT E459352T1
- Authority
- AT
- Austria
- Prior art keywords
- heterocyclic group
- substituted heterocyclic
- cannabinoid agonists
- compounds
- benzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06116564 | 2006-07-04 | ||
| PCT/EP2007/056619 WO2008003665A1 (en) | 2006-07-04 | 2007-07-02 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE459352T1 true ATE459352T1 (de) | 2010-03-15 |
Family
ID=37453123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07786974T ATE459352T1 (de) | 2006-07-04 | 2007-07-02 | Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8524757B2 (de) |
| EP (1) | EP2081572B1 (de) |
| JP (1) | JP5345528B2 (de) |
| KR (1) | KR20090024789A (de) |
| CN (1) | CN101621998B (de) |
| AT (1) | ATE459352T1 (de) |
| AU (1) | AU2007271241A1 (de) |
| BR (1) | BRPI0714199A2 (de) |
| CA (1) | CA2654246A1 (de) |
| CY (1) | CY1110342T1 (de) |
| DE (1) | DE602007005160D1 (de) |
| DK (1) | DK2081572T3 (de) |
| EA (1) | EA200970080A1 (de) |
| ES (1) | ES2341188T3 (de) |
| HK (1) | HK1139058A1 (de) |
| IL (1) | IL196289A0 (de) |
| MX (1) | MX2009000149A (de) |
| PL (1) | PL2081572T3 (de) |
| PT (1) | PT2081572E (de) |
| SI (1) | SI2081572T1 (de) |
| WO (1) | WO2008003665A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101412339B1 (ko) | 2004-07-15 | 2014-06-25 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도 |
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| JP5504153B2 (ja) * | 2007-03-30 | 2014-05-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイミダゾールカンナビノイドアゴニスト |
| CN101896471A (zh) * | 2007-12-17 | 2010-11-24 | 詹森药业有限公司 | 氟代烷基取代的苯并咪唑大麻素激动剂 |
| AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| KR20110117146A (ko) * | 2009-01-22 | 2011-10-26 | 라퀄리아 파마 인코포레이티드 | Ｃｂ2 수용체 효능활성이 있는 ｎ-치환 포화 헤테로사이클릭 술폰 화합물 |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| JP5735962B2 (ja) * | 2009-07-23 | 2015-06-17 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 新規なアルコキシエノンおよびエナミノケトンおよびその調製方法 |
| CA2770866C (en) | 2009-08-28 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP4166552A1 (de) | 2011-02-25 | 2023-04-19 | Arena Pharmaceuticals, Inc. | Kristalline formen und verfahren zur herstellung von kondensierten azacyclen (cannabinoid-rezeptormodulatoren) |
| JP6043733B2 (ja) | 2011-02-25 | 2016-12-14 | アリーナ ファーマシューティカルズ， インコーポレイテッド | カンナビノイド受容体モジュレーター |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08272028A (ja) * | 1995-03-30 | 1996-10-18 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその製造方法 |
| JPH08283590A (ja) | 1995-04-20 | 1996-10-29 | Fuji Photo Film Co Ltd | シアニン化合物および染料組成物 |
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| JP2008518905A (ja) * | 2004-11-02 | 2008-06-05 | ファイザー株式会社 | スルホニルベンゾイミダゾール誘導体 |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
-
2007
- 2007-07-02 WO PCT/EP2007/056619 patent/WO2008003665A1/en active Application Filing
- 2007-07-02 EP EP07786974A patent/EP2081572B1/de active Active
- 2007-07-02 EA EA200970080A patent/EA200970080A1/ru unknown
- 2007-07-02 JP JP2009517236A patent/JP5345528B2/ja not_active Expired - Fee Related
- 2007-07-02 BR BRPI0714199-8A patent/BRPI0714199A2/pt not_active Application Discontinuation
- 2007-07-02 AT AT07786974T patent/ATE459352T1/de active
- 2007-07-02 SI SI200730225T patent/SI2081572T1/sl unknown
- 2007-07-02 KR KR1020097000568A patent/KR20090024789A/ko not_active Application Discontinuation
- 2007-07-02 CA CA002654246A patent/CA2654246A1/en not_active Abandoned
- 2007-07-02 PT PT07786974T patent/PT2081572E/pt unknown
- 2007-07-02 CN CN2007800230162A patent/CN101621998B/zh not_active Expired - Fee Related
- 2007-07-02 ES ES07786974T patent/ES2341188T3/es active Active
- 2007-07-02 DK DK07786974.1T patent/DK2081572T3/da active
- 2007-07-02 MX MX2009000149A patent/MX2009000149A/es not_active Application Discontinuation
- 2007-07-02 US US12/307,512 patent/US8524757B2/en active Active
- 2007-07-02 PL PL07786974T patent/PL2081572T3/pl unknown
- 2007-07-02 AU AU2007271241A patent/AU2007271241A1/en not_active Abandoned
- 2007-07-02 DE DE602007005160T patent/DE602007005160D1/de active Active
-
2008
- 2008-12-31 IL IL196289A patent/IL196289A0/en unknown
-
2010
- 2010-05-25 HK HK10105112.0A patent/HK1139058A1/xx not_active IP Right Cessation
- 2010-06-03 CY CY20101100493T patent/CY1110342T1/el unknown
-
2013
- 2013-08-06 US US13/959,980 patent/US9284303B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090024789A (ko) | 2009-03-09 |
| PL2081572T3 (pl) | 2010-07-30 |
| DK2081572T3 (da) | 2010-06-07 |
| DE602007005160D1 (de) | 2010-04-15 |
| EP2081572A1 (de) | 2009-07-29 |
| JP5345528B2 (ja) | 2013-11-20 |
| HK1139058A1 (en) | 2010-09-10 |
| PT2081572E (pt) | 2010-05-17 |
| SI2081572T1 (sl) | 2010-06-30 |
| CY1110342T1 (el) | 2015-01-14 |
| CN101621998A (zh) | 2010-01-06 |
| BRPI0714199A2 (pt) | 2012-12-25 |
| AU2007271241A1 (en) | 2008-01-10 |
| EA200970080A1 (ru) | 2009-06-30 |
| WO2008003665A1 (en) | 2008-01-10 |
| US20130324529A1 (en) | 2013-12-05 |
| US8524757B2 (en) | 2013-09-03 |
| MX2009000149A (es) | 2009-01-23 |
| CA2654246A1 (en) | 2008-01-10 |
| IL196289A0 (en) | 2009-09-22 |
| EP2081572B1 (de) | 2010-03-03 |
| CN101621998B (zh) | 2013-12-18 |
| US20090312339A1 (en) | 2009-12-17 |
| US9284303B2 (en) | 2016-03-15 |
| ES2341188T3 (es) | 2010-06-16 |
| JP2009541453A (ja) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE459352T1 (de) | Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe | |
| ATE533762T1 (de) | Chinolin- oder isochinolinsubstituierte p2x7- antagonisten | |
| WO2009071631A3 (en) | Dibenzoazepine and dibenzooxazepine trpa1 agonists | |
| RS20080411A (en) | Amine derivatives | |
| SV2009003233A (es) | Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide | |
| PE20091324A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
| MX2010005997A (es) | Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales. | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| EA200501504A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
| EA201170151A1 (ru) | Пиперидиниловые агонисты gpcr | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| ATE473221T1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten | |
| ECSP099573A (es) | Derivados heterocíclicos como receptores muscarínicos m3 | |
| MX2007004661A (es) | Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3. | |
| MA32945B1 (fr) | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique | |
| DE602005007765D1 (de) | Neue indol- oder benzimidazol-derivate | |
| IN2012DN00953A (de) | ||
| JO3126B1 (ar) | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 | |
| BRPI0820838B8 (pt) | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3 | |
| EA201001842A1 (ru) | Новые соединения, обладающие активностью антагонистов мускариновых рецепторов | |
| EA201070462A1 (ru) | Антагонисты рецептора 5-нт |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2081572 Country of ref document: EP |